Patient characteristics at baseline
| Variables . | n = 13 . |
|---|---|
| Age at diagnosis, median (range) | 52 (43-70) |
| Age at combination BTKi and venetoclax initiation, median (range) | 63 (52-78) |
| Sex (%) | |
| Female | 2 (15) |
| Male | 11 (85) |
| Race | |
| White | 12 (92) |
| Other | 1 (8) |
| Total number of lines of chemo, median (range) | 8 (3-19) |
| Number of lines of chemo prior to combination start, median (range) | 6 (2-17) |
| Presence of bulky diseasea prior to combination start, n = 12b (%) | 6 (50) |
| IgHV unmutated (%) | 13 (100) |
| Stimulated karyotype complexity (%) | |
| Less than three abnormalities | 6 (46) |
| Three or more abnormalities | 7 (54) |
| FISH abnormalities (%) | |
| del(17p) | 4 (31) |
| del(11q) | 4 (31) |
| del(13q) | 2 (15) |
| Trisomy 12 | 4 (31) |
| Other FISH abnormalities | 5 (38) |
| TP53 mutation (%) | 3 (27) |
| Unknown | 2 |
| SF3B1 mutation (%) | 2 (20) |
| Unknown | 3 |
| NOTCH1 mutation (%) | 1 (10) |
| Unknown | 3 |
| BTKi mutation (%) | 8 (67) |
| Unknown | 1 |
| PLCG2 hotspot mutation (%) | 2 (17) |
| Unknown | 1 |
| Other less common mutations (%) | 8 (73) |
| Unknown | 2 |
| Variables . | n = 13 . |
|---|---|
| Age at diagnosis, median (range) | 52 (43-70) |
| Age at combination BTKi and venetoclax initiation, median (range) | 63 (52-78) |
| Sex (%) | |
| Female | 2 (15) |
| Male | 11 (85) |
| Race | |
| White | 12 (92) |
| Other | 1 (8) |
| Total number of lines of chemo, median (range) | 8 (3-19) |
| Number of lines of chemo prior to combination start, median (range) | 6 (2-17) |
| Presence of bulky diseasea prior to combination start, n = 12b (%) | 6 (50) |
| IgHV unmutated (%) | 13 (100) |
| Stimulated karyotype complexity (%) | |
| Less than three abnormalities | 6 (46) |
| Three or more abnormalities | 7 (54) |
| FISH abnormalities (%) | |
| del(17p) | 4 (31) |
| del(11q) | 4 (31) |
| del(13q) | 2 (15) |
| Trisomy 12 | 4 (31) |
| Other FISH abnormalities | 5 (38) |
| TP53 mutation (%) | 3 (27) |
| Unknown | 2 |
| SF3B1 mutation (%) | 2 (20) |
| Unknown | 3 |
| NOTCH1 mutation (%) | 1 (10) |
| Unknown | 3 |
| BTKi mutation (%) | 8 (67) |
| Unknown | 1 |
| PLCG2 hotspot mutation (%) | 2 (17) |
| Unknown | 1 |
| Other less common mutations (%) | 8 (73) |
| Unknown | 2 |
BTKi, Bruton tyrosine kinase inhibitor; BTKi mutation, mutation at site known to confer resistance to BTKi; del, chromosome deletion; FISH, fluorescent in situ hybridization; IgHV, immunoglobulin heavy chain.
aBulky disease was defined as largest lymph node >5 cm on advanced radiographic imaging.
bOne patient did not have pre-combination therapy imaging available for review.